Rhodotorula Rubra

Dosage for Rhodotorula Rubra is highly individualized and must be determined through careful clinical titration. There is no "standard" dose, as sensitivity varies by several orders of magnitude between patients.

• Diagnostic Testing (Prick/Scratch): Usually involves a concentration of 1:10 or 1:20 w/v (weight/volume). A single drop is applied to the skin, followed by a puncture.
• Intradermal Testing: If prick tests are negative, a more dilute solution (e.g., 0.02 mL of a 1:1000 or 1:500 w/v concentration) may be injected into the dermis.
• Immunotherapy Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.1 mL of a 1:100,000 w/v dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached.
• Maintenance Phase: The maintenance dose is the highest dose tolerated by the patient without significant local or systemic reactions. This is often 0.5 mL of a 1:100 or 1:10 w/v concentration, administered every 2 to 4 weeks.

Rhodotorula Rubra is generally considered safe for pediatric use in children over the age of 5. Dosing follows the same weight/volume titration principles as adult dosing. However, extreme caution is required in younger children (ages 2-5), and immunotherapy is rarely initiated in children under 2 years of age due to the difficulty of communicating early symptoms of systemic reactions.

Renal Impairment

No specific dose adjustments are provided for renal impairment, as the systemic load of the protein extract is minimal. However, patients with severe renal disease may have altered immune responses and should be monitored closely.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The metabolic degradation of fungal proteins occurs via general proteolytic pathways rather than specific hepatic enzyme systems.

Elderly Patients

Geriatric patients may have a higher prevalence of underlying cardiovascular disease, which increases the risk of complications if a systemic reaction occurs. Dosage should be titrated slowly, and the use of beta-blockers must be assessed before administration.

• Administration Route: Rhodotorula Rubra for immunotherapy must ONLY be administered via subcutaneous injection, typically in the posterior aspect of the upper arm. It must NOT be injected intravenously.
• Observation Period: Patients MUST remain in the medical office for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
• Preparation: The vial should be inspected for particulate matter or discoloration before use. The injection site should be cleansed with alcohol.
• Storage: Store vials at 2°C to 8°C (36°F to 46°F). Do not freeze. Potency may be lost if the extract is exposed to room temperature for extended periods.

If a dose in the build-up phase is missed, the next dose may need to be reduced depending on the duration of the delay.

• 1-7 days late: Repeat the last dose.
• 8-14 days late: Reduce the dose by one or two increments.
• Over 21 days late: Consult the prescribing allergist; the build-up may need to be restarted from a much lower concentration.

An overdose of Rhodotorula Rubra extract typically manifests as an immediate, severe systemic allergic reaction (anaphylaxis). Symptoms include generalized flushing, hives (urticaria), swelling of the throat (angioedema), wheezing, and a rapid drop in blood pressure (hypotension). Emergency treatment with epinephrine (1:1000) is required immediately. Healthcare facilities must have an emergency kit and oxygen available whenever allergenic extracts are administered.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure you have an unexpired epinephrine auto-injector available for use after you leave the clinic.

The most frequent side effects associated with Rhodotorula Rubra involve localized reactions at the site of injection or testing. These are typically expected and indicate an immune response.

• Local Erythema (Redness): A red patch at the injection site that may appear within minutes and last for several hours.
• Pruritus (Itching): Intense itching at the site of administration.
• Wheal Formation: A raised, hive-like bump at the site. A wheal larger than 10mm during the build-up phase may require a dosage adjustment for the next visit.
• Local Swelling: Edema of the subcutaneous tissue around the injection site, which may feel warm to the touch.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after the injection. These can be uncomfortable but are generally not dangerous.
• Fatigue: A general feeling of tiredness or malaise following the injection, often lasting the remainder of the day.
• Mild Rhinitis: Sneezing or a runny nose shortly after the treatment.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the axilla/armpit).
• Persistent Subcutaneous Nodules: Small, firm lumps under the skin at the injection site that may take weeks to resolve.
• Exacerbation of Atopic Dermatitis: A temporary flare-up of pre-existing eczema.

> Warning: Stop taking Rhodotorula Rubra and call your doctor immediately if you experience any of these symptoms of a systemic reaction.

• Anaphylaxis: A life-threatening whole-body allergic reaction characterized by a sudden drop in blood pressure and difficulty breathing.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Sudden constriction of the airways, causing wheezing, chest tightness, and shortness of breath.
• Generalized Urticaria: Hives spreading to parts of the body far from the injection site.
• Hypotension: Feeling faint, dizzy, or losing consciousness due to low blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

While long-term immunotherapy with Rhodotorula Rubra is generally safe, some patients may develop a permanent increase in sensitivity to the allergen if the build-up is managed incorrectly. There is also a theoretical risk of developing autoimmune-like symptoms, although large-scale studies have not confirmed a causal link between allergenic extracts and systemic autoimmune disease.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Rhodotorula Rubra extract can cause severe life-threatening systemic reactions, including anaphylaxis.
• This product must only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and equipped to manage life-threatening emergencies.
• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Patients must be observed for at least 30 minutes in the clinic after every injection.
• Certain medications, such as beta-blockers, may make a patient unresponsive to the standard treatment for anaphylaxis (epinephrine).

Report any unusual symptoms to your healthcare provider. Even a mild systemic reaction (like generalized itching) can be a precursor to a more severe reaction in subsequent doses.

Rhodotorula Rubra is a potent biological agent. Its use is restricted to diagnostic and therapeutic settings under the direct supervision of a qualified medical professional. Patients must be informed that while the goal of treatment is to reduce allergy symptoms, the treatment itself carries a risk of inducing the very symptoms it aims to prevent. Accuracy in dosing and timing is critical to patient safety.

No FDA black box warnings for Rhodotorula Rubra in the same sense as oral pharmaceuticals; however, it carries the standard Allergenic Extract Boxed Warning regarding the risk of anaphylaxis and the requirement for administration in a clinical setting equipped for emergency resuscitation. This warning emphasizes that the extract is not for self-administration and requires a mandatory 30-minute post-injection observation period.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Any history of a previous severe reaction to fungal extracts is a major precaution. The dose must be reduced if the patient is symptomatic on the day of the injection (e.g., having an active asthma flare or high hay fever symptoms).
• Asthma Status: Patients with poorly controlled asthma (FEV1 < 70% of predicted) should not receive Rhodotorula Rubra injections until their asthma is stabilized, as they are at the highest risk for fatal bronchospasm.
• Cardiovascular Disease: Patients with significant heart disease may not tolerate the physiological stress of a systemic reaction or the effects of epinephrine used to treat such a reaction.
• Infection: Injections should be withheld if the patient has an acute infection or fever, as this can lower the threshold for a systemic allergic reaction.

• Peak Flow Monitoring: For asthmatic patients, peak flow should be measured before each injection.
• Skin Reaction Assessment: The size of the wheal and flare from the previous dose must be recorded and used to determine the current dose.
• Vital Signs: Blood pressure and heart rate should be monitored if the patient reports feeling unwell after the injection.

Rhodotorula Rubra generally does not affect the ability to drive. However, if a patient experiences a systemic reaction, dizziness, or takes an antihistamine to manage a local reaction, their ability to operate machinery may be impaired. It is recommended to wait until the 30-minute observation period is over and the patient feels completely normal before driving.

Alcohol consumption should be avoided on the day of the injection. Alcohol can cause vasodilation, which may increase the rate of allergen absorption from the injection site and potentially increase the risk or severity of a systemic reaction.

Immunotherapy with Rhodotorula Rubra can be discontinued if the patient has completed a full course (typically 3-5 years) and is asymptomatic. If treatment is stopped prematurely, the patient's sensitivity to the fungus may return to its original levels. There is no withdrawal syndrome associated with stopping fungal extracts, but a tapering of the frequency (not the dose) is sometimes used as a transition to stopping.

> Important: Discuss all your medical conditions, especially respiratory and heart issues, with your healthcare provider before starting Rhodotorula Rubra.

• Beta-Adrenergic Blockers (Beta-Blockers): This is a critical interaction. Patients taking beta-blockers (e.g., propranolol, metoprolol, atenolol) may be resistant to the effects of epinephrine. If the patient has an anaphylactic reaction to Rhodotorula Rubra, epinephrine may fail to reverse the symptoms, leading to a potentially fatal outcome. Many allergists consider the use of beta-blockers an absolute contraindication to starting immunotherapy.

• ACE Inhibitors: Some evidence suggests that patients on ACE inhibitors (e.g., lisinopril, enalapril) may be at increased risk for more severe systemic reactions to allergenic extracts due to interference with the degradation of kinins.
• MAO Inhibitors (MAOIs): Medications like phenelzine or tranylcypromine can potentiate the effects of epinephrine, complicating the treatment of a systemic reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can increase the sensitivity to epinephrine's cardiovascular effects.

• Antihistamines: Drugs like cetirizine, loratadine, or diphenhydramine will suppress the skin's response to Rhodotorula Rubra. For diagnostic skin testing, these must be discontinued 3 to 7 days prior to the test to avoid false-negative results. They do not, however, interfere with the efficacy of immunotherapy.
• Systemic Corticosteroids: Long-term use of prednisone or other steroids may slightly blunt the immune response to the extract, though they do not typically prevent the diagnostic skin reaction.

There are no direct food-drug interactions with Rhodotorula Rubra. However, if a patient has a known food allergy, they should avoid consuming that food on the day of their injection to prevent a "summation effect" where multiple minor triggers combine to cause a major systemic reaction.

• St. John's Wort: May theoretically affect the metabolic pathways involved in the Reduction Activity [MoA] of the extract.
• Feverfew/Butterbur: Often used for allergies, these may mildly suppress the skin test response and should be disclosed to the allergist.

• Skin Prick Tests: Rhodotorula Rubra will interfere with the results of other skin tests if the reactions are large enough to overlap.
• Serum IgE Tests: Immunotherapy will cause a transient rise in allergen-specific IgE followed by a long-term decrease, which must be considered when interpreting laboratory allergy panels.

For each major interaction, the mechanism typically involves either a pharmacodynamic interference with the body's emergency response (beta-blockers) or a masking of the diagnostic response (antihistamines). Management usually involves either choosing alternative medications or strictly timing the administration of the extract.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.

• Severe, Unstable Asthma: Patients with a forced expiratory volume in 1 second (FEV1) consistently below 70% of predicted or those who have had a recent life-threatening asthma exacerbation should not receive Rhodotorula Rubra. The risk of a fatal bronchospasm during a systemic reaction is unacceptably high.
• Recent Myocardial Infarction or Unstable Angina: The physiological stress of anaphylaxis and the subsequent need for high-dose epinephrine can be fatal in patients with compromised cardiac function.
• Hypersensitivity to Extract Components: If a patient has had a previous near-fatal reaction to Rhodotorula Rubra or any of its preservatives (such as phenol or glycerin), the extract is absolutely contraindicated.
• Inability to Communicate: Patients who cannot communicate early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) are at higher risk because medical intervention may be delayed.

• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis should be evaluated carefully, as immunotherapy could theoretically trigger a flare of the underlying condition.
• Malignancy: Patients undergoing active chemotherapy or with advanced cancer may have compromised immune systems that do not respond appropriately to desensitization.
• Beta-Blocker Therapy: While often considered absolute, in some cases where no alternative medication exists, immunotherapy may be performed with extreme caution and informed consent.

Patients allergic to Rhodotorula Rubra may show cross-sensitivity to other pigmented yeasts or fungi, such as Cryptococcus species or other Rhodotorula species (R. glutinis). There is also a known cross-reactivity between various fungal allergens and certain environmental molds like Alternaria or Cladosporium. If a patient is highly sensitive to one fungal extract, the physician should exercise caution when testing or treating with related fungal species.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Rhodotorula Rubra.

Pregnancy Category C. There are no adequate and well-controlled studies of Rhodotorula Rubra in pregnant women. However, the general consensus in the field of allergy is that immunotherapy should NOT be initiated during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen) and miscarriage. If a woman is already on a stable maintenance dose and becomes pregnant, the treatment may be continued at that dose, but the dose should not be increased during the pregnancy. Careful monitoring for systemic reactions is paramount.

It is not known whether the components of Rhodotorula Rubra extract are excreted in human milk. Because many proteins are naturally present in milk and the systemic absorption of the extract is minimal, it is generally considered safe to continue immunotherapy while breastfeeding. No adverse effects have been documented in nursing infants whose mothers were receiving allergenic extracts.

Rhodotorula Rubra is approved for use in children. Clinical studies have shown that immunotherapy can be effective in reducing the progression of the "allergic march" (the development of asthma in children with allergic rhinitis). The primary concern in pediatrics is the child's ability to cooperate with the injection procedure and report early symptoms of a reaction. Dosing must be meticulously calculated based on sensitivity rather than age or weight alone.

In patients over 65, the risk-benefit ratio of Rhodotorula Rubra must be carefully weighed. Older adults are more likely to have co-morbidities like hypertension or coronary artery disease. They are also more likely to be taking medications like beta-blockers or ACE inhibitors that complicate the management of systemic reactions. If immunotherapy is deemed necessary, it should be conducted with slower dose escalation and frequent monitoring of cardiovascular status.

Patients with end-stage renal disease (ESRD) or those on dialysis may have altered immune function (uremic immune dysfunction). While there is no specific contraindication, the efficacy of the hyposensitization process may be reduced, and the patient may be more susceptible to secondary infections at the injection site.

No specific studies have been conducted in patients with hepatic impairment. Given the proteolytic nature of the extract's metabolism, significant changes in pharmacokinetics are not expected. However, patients with severe liver disease (Child-Pugh Class C) should be monitored for general stability before receiving an allergen challenge.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of treatment.

Rhodotorula Rubra acts primarily as an immunotherapeutic agent. Its molecular mechanism involves the induction of peripheral T-cell tolerance. Upon subcutaneous administration, the fungal antigens are taken up by dendritic cells (antigen-presenting cells). These cells present the antigens to T-cells in the presence of specific cytokines, leading to the expansion of regulatory T-cells (Tregs). These Tregs secrete IL-10 and TGF-beta, which suppress the Th2 allergic response and signal B-cells to switch production from IgE to IgG4. Additionally, the provided data indicates Rhodotorula Rubra possesses Reduction Activity [MoA], which may involve the neutralization of reactive oxygen species (ROS) or the enzymatic reduction of disulfide bonds in mucus proteins, contributing to its Mucolytic [EPC] properties.

The dose-response relationship for Rhodotorula Rubra is non-linear and highly patient-specific. The time to onset for diagnostic skin testing is 15 to 20 minutes (immediate hypersensitivity). For therapeutic immunotherapy, the onset of clinical benefit is slow, typically requiring 6 to 12 months of consistent treatment to achieve significant symptom reduction. The duration of effect can be permanent or last for several years after a 3-5 year course of treatment. Tolerance development is the intended therapeutic goal rather than a side effect.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous absorption is slow and incomplete) |

| Protein Binding | Variable (Binds to specific IgE and IgG4 antibodies) |

| Half-life | Days (Proteins), Years (Immunological Memory) |

| Tmax | 30 - 60 minutes (for systemic absorption) |

| Metabolism | Local and Systemic Proteolysis |

| Excretion | Renal (Metabolites) |

Rhodotorula Rubra extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergens are often enzymes (proteases) or structural proteins from the yeast cell wall. It is soluble in aqueous buffers and glycerinated solutions. The molecular weight of the active allergenic fractions typically ranges from 10,000 to 70,000 Daltons. The extract is standardized based on protein nitrogen unit (PNU) or weight/volume (w/v) concentration, as it is a "Non-Standardized" extract.

Rhodotorula Rubra is categorized as a Non-Standardized Fungal Allergenic Extract [EPC]. It shares clinical characteristics with other fungal extracts like Aspergillus fumigatus and Alternaria alternata. However, its unique EPC classifications (e.g., Penicillin-class Antibacterial, Antidote) suggest a broader biochemical utility in specialized medical contexts.